Mukesh Sanghadia
Psychiatry · Garberville, CANPI 1366550246
Payments from drug & device makers
Across 875 payments — averaging $109.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$48K
- Neurocrine Biosciences, Inc.$31K
- AbbVie$6K
- Johnson & Johnson$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $5K from 12 others
What the payments were for
- Consulting fees$11,24812%
- Speaking & faculty fees$60,25063%
- Travel & lodging$3,8684%
- Food & beverage$19,91921%
- Education$3210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 140 | $47,671 |
| Neurocrine Biosciences, Inc. | 133 | $31,238 |
| AbbVie(2 entities) | 124 | $5,886 |
| Johnson & Johnson | 74 | $1,914 |
| Alkermes, Inc. | 71 | $1,848 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,685 |
| Otsuka America Pharmaceutical, Inc. | 80 | $1,333 |
| Indivior Inc. | 50 | $1,037 |
| Vanda Pharmaceuticals Inc. | 58 | $991 |
| Lundbeck LLC | 38 | $692 |
| Sunovion Pharmaceuticals Inc. | 28 | $559 |
| Axsome Therapeutics, Inc. | 5 | $275 |
| Novartis | 2 | $121 |
| Neurelis, Inc. | 1 | $118 |
| GSK | 2 | $115 |
| Eisai Inc. | 3 | $67 |
| Noven Therapeutics, LLC | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$29,046
- UZEDY$22,748
- Austedo XR$16,153
- AUSTEDO$5,924
- VRAYLAR$4,114
- LYBALVI$1,805
- ARISTADA$960
- SPRAVATO$375
- CAPLYTA$349
- ARISTADA INITIO$240
- Auvelity$231
- LATUDA$122
- INVEGA SUSTENNA$119
- VALTOCO$118
- REXULTI$114
- INVEGA TRINZA$107
- NUCALA$101
How this compares
$95,606 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 72 | $153,713 |
| IngrezzaValbenazine Tosylate | 56 | $133,947 |
| UzedyRisperidone | 37 | $123,314 |
| Invega SustennaPaliperidone Palmitate | 33 | $114,419 |
| Abilify MaintenaAripiprazole | 36 | $96,146 |
| VraylarCariprazine Hcl | 80 | $65,510 |
| FanaptIloperidone | 33 | $30,015 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $24,863 |
| RexultiBrexpiprazole | 28 | $24,182 |
| VivitrolNaltrexone Microspheres | 12 | $18,318 |
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $9,931 |
| Lurasidone Hcl | 19 | $5,035 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $4,322 |
| DayvigoLemborexant | 14 | $4,178 |
| Clozapine | 22 | $2,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $47,671 | $277,027109 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $31,238 | $133,94756 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,333 | $120,32864 claims |
| Johnson & JohnsonInvega Sustenna | $1,914 | $114,41933 claims |
| AbbVieVraylar | $5,886 | $65,51080 claims |
| Alkermes, Inc.Lybalvi, Vivitrol | $1,848 | $43,18130 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $991 | $30,01533 claims |
| Axsome Therapeutics, Inc.Auvelity | $275 | $9,93127 claims |
| Eisai Inc.Dayvigo | $67 | $4,17814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Garberville
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.